Highlights on the First Line Treatment of Metastatic Pancreatic Cancer

Highlights from the “2012 ASCO Annual Meeting”, Chicago, IL, USA; May 31 - June 5, 2012

Krishna S Gunturu\(^1\), Jamie Jarboe\(^1\), Muhammad Wasif Saif\(^2\)

\(^1\)Division of Hematology/Onocology and \(^2\)Department of Medicine and Cancer Center, Tufts Medical Center. Boston, MA, USA

Summary
Pancreatic cancer is the fourth leading cause of cancer deaths in men and women. The estimated deaths from pancreatic cancer in 2012 in the United States are 37,390, and the five-year survival for all patients with pancreatic adenocarcinoma is less than 5%. Majority of patients present with incurable metastatic pancreatic cancer. The 2012 American Society of Oncology (ASCO) Annual Meeting offered new insights into metastatic pancreatic cancer and we discuss Abstracts #4018, #4019, #4022, #4042, #4043, #4048, #4050 and comment on them in this paper.

What We Knew Before the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting
Pancreatic cancer is the fourth leading cause of cancer deaths in men and women [1]. The estimated deaths from pancreatic cancer in 2012 in the United States are 37,390, and the five-year survival for all patients with pancreatic adenocarcinoma is less than 5% [2]. Metastatic pancreatic cancer remains a difficult disease to cure. Gemcitabine has been the standard of care for pancreatic cancer for a long time. Even though gemcitabine is tolerated well, its efficacy is marginal with median survival of less than 7 months in metastatic pancreatic cancer patients [3, 4]. Combination chemotherapy with gemcitabine has thus far shown no meaningful survival in metastatic pancreatic cancer [5, 6, 7]. In 2010, Conroy et al. presented the data with combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) compared with gemcitabine in metastatic pancreatic cancer patients which showed impressive efficacy, but with major toxicity profile [8]. The median overall survival with this combination was 11.1 months vs. 6.8 months in gemcitabine arm. Progression free survival and response rates were significantly improved with FOLFIRINOX (6.4 vs. 3.3 months and 31.6% vs. 9.4%, respectively). Since then, FOLFIRINOX has been the standard of care in good performance metastatic pancreatic cancer patients.

What We Learnt at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting
This paper summarizes the abstract presentations of metastatic pancreatic cancer at recent ASCO Annual Meeting (Table 1).

FOLFIRI.3 (CPT-11 plus Folinic Acid plus 5-FU) Alternating with Gemcitabine or Gemcitabine alone in Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma (MPA): Results of the Randomized Multicenter AGEO Phase II Trial FIRGEM (Abstract #4018) [9]

CPT-11 (irinotecan) has been shown to be efficacious in metastatic pancreatic adenocarcinoma. Conroy, et al. showed dramatic improvement in overall survival with the use of CPT-11 in the FOLFIRINOX regimen; however, there was considerable toxicity [8]. The authors of this abstract present result from the FIRGEM trial that has investigated a new strategy to improve tolerability and efficacy of CPT-11 in metastatic pancreatic adenocarcinoma.

This phase II study enrolled 98 patients in France between 2007 and 2011. Of these 59 patients were males and the median age was 62 years. Performance status was 0-1 and the median follow-up was 23 months. Patients were randomized to 5-fluorouracil, leucovorin (folic acid), irinotecan (CPT-11) (FOLFIRI.3) for 2 months alternating with gemcitabine.
Table 1. 2012 American Society of Clinical Oncology (ASCO) Annual Meeting: metastatic pancreatic cancer abstracts.

<table>
<thead>
<tr>
<th>Author/abstract</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trouilloud et al. #4018 [9]</td>
<td>FOLFIRI3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): Results of the randomized multicenter AGEO phase II trial FIRGEM.</td>
</tr>
<tr>
<td>Philip et al. #4019 [10]</td>
<td>Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: Phase I/randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG-0727).</td>
</tr>
<tr>
<td>Catenauci et al. #4022 [14]</td>
<td>A phase IIb/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study.</td>
</tr>
<tr>
<td>Fuchs et al. #4042 [16]</td>
<td>A phase III trial of ganitumab (GAN, AMG 479) with gemcitabine (G) as first-line treatment (tx) in patients (pts) with metastatic pancreatic cancer (MPC): An analysis of safety from the GAMMA trial (GEM and AMG 479 in Metastatic Adenocarcinoma of the Pancreas).</td>
</tr>
<tr>
<td>Ocean et al. #4043 [18]</td>
<td>Phase I/II study of 10⁹-civatuzumab tetraxetan (10⁹-hPAM4) combined with gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results.</td>
</tr>
<tr>
<td>Truong et al. #4048 [22]</td>
<td>A phase I study of nab-paclitaxel (A), gemcitabine (GEM), and capecitabine (X) in patients with metastatic pancreatic adenocarcinoma (MPA).</td>
</tr>
</tbody>
</table>

Table 2. Details of the randomized multicenter AGEO phase II trial FIRGEM (Abstract #4018) [9].

<table>
<thead>
<tr>
<th>Arm A</th>
<th>Arm B</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Drug schedule</strong></td>
<td><strong>Gemcitabine</strong></td>
</tr>
<tr>
<td>FOLFIRI3 + gemcitabine</td>
<td>1,000 mg/m² at a fixed dose rate of 10 mg/m²/min on days 1, 15, 29, 36 and 43</td>
</tr>
<tr>
<td>CPT-11 (irinotecan) 90 mg/m² as a 60 min infusion on day 1, leucovorin 400 mg/m² as a 2 h infusion on day 1, followed by 5-FU 2,000 mg/m² as 46 h infusion and CPT-11 90 mg/m², repeated on day 3, at the end of the 5-FU infusion, every two weeks for 2 months alternating with gemcitabine 1,000 mg/m² at a fixed dose rate of 10 mg/m²/min on days 1, 8, 15, 29, 36 and 43 for 2 months</td>
<td></td>
</tr>
</tbody>
</table>

**Results:**
- **Response rates**
  - 40% |
  - 73% |
- **Disease control rate (CR+PR+SD)**
  - 40% (95% CI: 33-63%) |
  - 52% (95% CI: 37-66%) |
- **6-month progression free survival**
  - 48% (95% CI: 33-63%) |
  - 30% (95% CI: 17-44%) |
- **12-month progression free survival**
  - 23% (95% CI: 11.5-36%) |
  - 11% (95% CI: 4.21-21%) |

**Toxicity:**
- **Diarrhea**
  - 13% |
  - 0 |
- **Nausea/vomiting**
  - 11% |
  - 4% |
- **Neutropenia**
  - 51% |
  - 25% |
- **Feverile neutropenia**
  - 4% |
  - 0 |

CI: confidence interval; CR: complete response; PR: partial response; SD: stable disease.
The phase I study demonstrated safety of the combination. The primary end point of the phase II study was progression free survival. One-hundred and twenty-four patients were evaluated with one hundred and fourteen eligible. Fifty-nine percent of patients were female in the experimental arm and forty percent in the control arm. The results are shown in Table 3. Toxicities were similar between the two arms with more grade 3-4 toxicities seen in the experimental arm. There were five treatment-related deaths reported (2 cardiac in each arm and 1 pulmonary in the experimental arm). The authors concluded that cixutumumab did not provide improvement in progression free survival or overall survival when combined with erlotinib and gemcitabine.

Gemcitabine (G) plus Placebo (P) or Vismodegib (V), a Hedgehog (Hh) Pathway Inhibitor, in Patients (pts) with Metastatic Pancreatic Cancer (PC): Interim Analysis of a University of Chicago Phase II Consortium Study (Abstract #4022) [14]

Activation of sonic hedgehog signaling occurs in the majority of pancreatic cancers [15]. Sonic hedgehog has been shown to act at multiple stages in the development of pancreatic cancer from enhancing proliferation of pancreatic epithelial cells to preventing apoptosis. It has also been shown to coordinate with activated K-ras to promote tumor development; suggesting a novel target for pancreatic cancer treatment.

This study is a multi-center, placebo-controlled, phase IB/randomized phase II trial of gemcitabine with vismodegib or placebo (GV vs GP) conducted at 12 centers in the United States from February 2010 to June 2011. Patients in this study had a good performance status and were either untreated with metastatic pancreatic cancer or had completed adjuvant therapy more than 6 months prior. Patient characteristics are reviewed in Table 4. Patients were stratified by Karnofsky performance status (KPS: 80 vs 90 vs 100) and disease status (newly diagnosed vs recurrent disease) and randomized to either gemcitabine plus vismodegib or gemcitabine plus placebo (drug schedule shown in Table 4). The primary

### Table 3. Details of the phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG-0727) [10].

<table>
<thead>
<tr>
<th>Drug schedule</th>
<th>Experimental arm (CEG)</th>
<th>Control arm (EG)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cixutumumab 6 mg/kg/wk i.v., erlotinib 100 mg/day orally, and gemcitabine 1,000 mg/m² i.v. at days 1, 8, and 15 of a 28-day cycle</td>
<td>Erlotinib 100 mg/day orally, and gemcitabine 1,000 mg/m² i.v. at days 1, 8, and 15 of a 28-day cycle</td>
<td></td>
</tr>
</tbody>
</table>

**Survival results:**
- Median progression free survival: 3.7 months vs 3.7 months
- Median overall survival: 6.7 months vs 6.7 months

**Grade 3-4 toxicity:**
- Elevation of transaminases: 12% vs 6%
- Fatigue: 16% vs 12%
- Gastrointestinal: 35% vs 28%
- Neutropenia: 21% vs 10%
- Thrombocytopenia: 16% vs 17%
- Hyperglycemia: 16% vs 0

### Table 4. Details of the gemcitabine plus vismodegib or placebo in patients with metastatic pancreatic cancer phase II Chicago consortium study [14].

<table>
<thead>
<tr>
<th>Drug schedule</th>
<th>Experimental arm (GV)</th>
<th>Control arm (GP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gemcitabine 1,000 mg/m² on days 1, 8, 15 of a 28-day cycle</td>
<td>Gemcitabine 1,000 mg/m² on days 1, 8, 15 of a 28-day cycle</td>
<td></td>
</tr>
<tr>
<td>Vismodegib 150 mg  po daily</td>
<td>Placebo</td>
<td></td>
</tr>
</tbody>
</table>

**Age:** median (range) 63 years (49-79 years) vs 63 years (48-82 years)

**Karnofsky performance status (KPS):**
- 80: 8 vs 8
- 90: 12 vs 14
- 100: 15 vs 13

**Response rate:**
- Complete response: 0 vs 3%
- Partial response: 0 vs 11%
- Stable disease: 49% vs 31%

**Progression free survival:**
- 3.7 months (95% CI: 2.4-4.6 months) vs 2.4 months (95% CI: 1.9-3.7 months)

**Median overall survival:**
- 6.3 months (95% CI: 4.9-7.8 months) vs 5.4 months (95% CI: 4.2-8.0 months)

**1-year survival:**
- 24% vs 24%

**Grade 3/4 toxicity:**
- Neutropenia: 20% vs 26%
- Hypotension: 3% vs 11%
- Fatigue: 9% vs 6%
- Hyperglycemia: 14% vs 6%
- Elevated alkaline phosphatase: 9% vs 11%
end-point of the study was progression free survival. Patients in the control (gemcitabine plus placebo) arm who demonstrated progression were allowed to cross-over to the experimental arm. This interim analysis was negative (but did not meet criteria for futility) with accrual completed in early 2012 and final report to be made after 90 events. Complete results from the abstract are listed in Table 4. The authors concluded that gemcitabine plus vismodegib has a tolerable toxicity profile and are awaiting the final analysis.

A Phase III trial of Ganitumab (GAN, AMG 479) with Gemcitabine (G) as First-Line Treatment (tx) in Patients (pts) with Metastatic Pancreatic Cancer (MPC): An Analysis of Safety from the GAMMA trial (GEM and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) (Abstract #4042) [16]

For more than a decade gemcitabine has been standard of care for advanced pancreatic cancer [3]. The addition of chemotherapy or targeted therapy to gemcitabine has not yielded any significant benefit [4, 7, 17]. The authors of this abstract presented an ongoing study of ganitumab in a phase III trial of metastatic pancreatic cancer.

This phase II study is taking place globally and is ongoing to evaluate the safety and efficacy of monocolonal antibody inhibitor of IGF-1R, ganitumab as first line treatment in metastatic pancreatic cancer. The estimated sample size is 825 and 207 patients were presented in this abstract. Of those, 204 patients received the study drug. Primary endpoint of the study is overall survival and secondary endpoints are progression free survival, safety and patient-reported outcomes. Drug schedule is presented in Table 5 and patient characteristics are presented in Table 6. Grade 3-4 adverse events in all three treatment arms reported include, neutropenia followed by thrombocytopenia, fatigue, hyperglycemia and liver function test abnormalities. Neutropenia has been a predominant side effect of the therapy. Ten patients died during or within 30 days of the termination of treatment.

Phase III Study of 90Y-Clivatuzumab Tetraxetan (90Y-hPAM4) Combined with Gemcitabine in Advanced Pancreatic Cancer (APC): Final Results (Abstract #4043) [18]

This abstract presents the final results of the phase I/II trial of 90Y-labeled humanized monoclonal antibody, 90Y-hPAM4, and gemcitabine with single or repeated cycles of fractionated radioimmunotherapy as a first line treatment in stage III or IV pancreatic cancer. Treatment was continued until progression, intolerable toxicity or study withdrawal. Table 7 details the therapy schedule and describes the results reported. Improvement in the performance status and pain control was also reported. The toxicities of the regimen are also reported in Table 7. Along with the adverse events reported in the table, infections requiring treatment and one case of bleeding were seen. Low dose gemcitabine 200 mg/m^2 was tolerated in combination with fractionated immunoradiotherapy (90Y-hPAM4) as first line treatment for stage 3-4 pancreatic cancer. Main dose limiting toxicity was hematological toxicity.

A Phase I Study of Nab-Paclitaxel, Gemcitabine, And Capecitabine in Patients with Metastatic Pancreatic Adenocarcinoma (Abstract #4048) [22]

Metastatic pancreatic cancer remains a lethal disease with no improvements in combination regimens. A phase III trial of gemcitabine in combination with capecitabine compared to gemcitabine alone showed increased response rate (P=0.034) and progression free survival (P=0.04), but no improvement in overall survival [23]. Hermann et al. in a phase III trial showed that gemcitabine and capecitabine did not improve the overall survival, but subgroup analysis showed combination of gemcitabine and capecitabine improved overall survival compared to single-agent gemcitabine [7]. Meta-analysis of 35 trials of gemcitabine combination regimens showed gemcitabine with capecitabine or oxaliplatin improved overall survival and objective response rate [24]. Here, we discuss the abstract presentation results of a phase I study of gemcitabine, capecitabine and nab-paclitaxel in first-line treatment of metastatic pancreatic cancer. Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 were eligible for...
participation. Treatment included nab-paclitaxel, gemcitabine, and capecitabine. Primary goal was to establish the maximum tolerated dose of the regimen and secondary goal is to assess the safety and efficacy of this regimen. Median age range for the enrolled 15 patients was 45-74 years. Initial dose level for this course of therapy was nab-paclitaxel 100 mg/m², gemcitabine 750 mg/m², and capecitabine 750 mg/m² bid and this was established as final maximum tolerated dose. Median number of cycles received was 4 (range: 2-16). Grade 3-4 toxicities were noted in 67% of the patients (10 out of 15 patients) with this combination regimen and included nausea, vomiting, fatigue and liver function test abnormalities. Other side-effects of all grades included fatigue in 87% of the patients, rash or hand foot syndrome in 67%, nausea and vomiting in 53%, diarrhea in 40% and neutropathy in 33% of the patients. Seventy-three percent of patients had progression of disease and discontinued the treatment. Of the 14 evaluable patients, response rates were 2 partial responses, 8 stable disease and 4 (range: 2-16) of 3 patients at dose level 2. Partial response was seen in 4 out of 10 patients at dose level 1 and one of 3 patients at dose level 2. There was no interaction noted between mg/m² possibly from the small sample size and the limitations of comparing two different studies. A Phase I/II Study of the MEK Inhibitor BAY 86-9766 (BAY) in Combination with Gemcitabine in Patients with Nonresectable, Locally Advanced or Metastatic Pancreatic Cancer: Phase I Dose-Escalation Results (Abstract #4050) [25]

K-ras mutations are found in approximately 90% of pancreatic cancers [26] and are present exclusively in the cancer cells. Cetuximab failed to show survival advantage in pancreatic cancer harboring K-ras mutation even with predominant K-ras mutation presence in pancreatic cancer [13]. Thus, targeting the RAS-RAF-MEK-ERK pathways may prove to be beneficial in the treatment of K-ras mutant pancreatic cancer.

This abstract presents the results of a phase I/II dose escalation study of the MEK inhibitor BAY 86-9766 and gemcitabine in pancreatic cancer patients. A 3+3 design was used for dose escalation. After dose level 2 of BAY 86-9766, no dose escalation was done. Table 8 shows the treatment details. Maximum tolerated dose was defined as the highest dose at which maximum 1 out of 6 patients had dose limiting toxicity during cycle 1. Seventeen patients were reported to receive treatment of which 10 were at dose level 1 and 7 were at dose level 2. Partial response was seen in 4 out of 10 patients at dose level 1 and one of 3 patients at dose level 2. There was no interaction noted between

| Table 8. Dosing schedule of a phase I dose-escalation study of the MEK inhibitor BAY 86-9766 in combination with gemcitabine in patients with nonresectable, locally advanced or metastatic pancreatic cancer (Abstract #4050) [25]. |
|---|---|---|---|
| **Gemcitabine** | **Cycle 1:** 1,000 mg/m² i.v. once weekly for 7 of 8 weeks | **Subsequent cycles:** 3 of 4 weeks | **BAY 86-9766** |
| **Dose level 1:** 50 mg bid (n=10) | Dose level 2: 50 mg bid (n=7) | **Dose level 1: 50 mg bid (n=10)** | **Dose level 2: 50 mg bid (n=7)** |

| Table 9. Toxicity profile, of a phase I dose-escalation study of the MEK inhibitor BAY 86-9766 in combination with gemcitabine in patients with nonresectable, locally advanced or metastatic pancreatic cancer (Abstract #4050) [25]. |
|---|---|---|
| **Toxicity** | **Grade 1-2** | **Grade 3-4** |
| Acneiform rash | 10 (58.8%) | 1 (5.9%) |
| Hepatic failure/death | - | 1 (5.9%) |
| Neutropenia | - | 6 (35.3%) |
gemcitabine and BAY 86-9766 at dose level 1. Table 9 shows the toxicity profile of this regimen. The most common side effect of BAY 86-9766 was acneiform rash. The conclusion of this abstract was that BAY 86-9766 and gemcitabine combination was tolerated well.

Discussion

Gemcitabine remains the standard of care in poor performance patients with metastatic pancreatic cancer patients. Trials with gemcitabine combinations, while well-tolerated, have provided little in the way of survival benefits. A number of abstracts were presented at ASCO examining new combinations. Combinations include traditional chemotherapeutic agents as well as targeted therapies. Preliminary data have not been promising in the realm of targeted agents with the hedgehog pathway inhibitor, MEK inhibitor as well as the EGFR and IGF-1R inhibitors with negative or equivocal preliminary results. Full assessment of these agents cannot be made until the final results are available; however, further investigation into combination agents should continue. Combinations with more traditional chemotherapeutic agents have been more promising but with increased toxicity as shown in the recent FOLFIRINOX study [8].

FOLFIRINOX has emerged as a standard regimen in good performance metastatic pancreatic cancer patients. The toxicity profile tempered the enthusiasm to use this regimen in the oncology world. An abstract presented at the 2012 ASCO Gastrointestinal Cancers Symposium showed that dose attenuations of FOLFIRINOX maintained its efficacy with improvement in the toxicity profile in advanced pancreatic cancer patients [27]. This should prompt further evaluation of FOLFIRINOX as the backbone for the future trials in advanced pancreatic cancer patients. The FIRGEM trial (Abstract #4018) [9] also shows that a more aggressive chemotherapy regimen, like FOLFIRI.3 could be alternated with gemcitabine to improve outcomes and augment toxicities. More information is needed from these and other ongoing clinical trials as the standard of care in metastatic pancreatic cancer continues to evolve.

Authors’ disclosures of potential conflicts of interest

Muhammad Wasif Saif: research funding (Infinity and Clovis); Krishna S Gunturu: None; Jamie Jarboe: None

References


